Evaluating the effect of Spirulina in Non-alcoholic ?fatty liver patient.

Evaluating the Effect of Spirulina Consumption on Anthropometric, Glucose, Lipid, Antioxidant, Inflammatory indices and Liver Enzymes in Non-Alcoholic ?Fatty Liver Patient.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200304046692N1

Enrollment

Registered

2020-03-11

Start date

2019-12-11

Completion date

Unknown

Last updated

2020-03-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-alcoholic fatty liver. Fatty (change of) liver, not elsewhere classified

Interventions

Intervention 1: Intervention group: For 8 weeks, they will receive 2 grams of spirulina daily in form of the sauce prepared at the Shiraz Namakin Factory.Each 20g sauce sachet contains 2 grams of spir

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Individuals with Non-alcoholic fatty liver disease

Exclusion criteria

Exclusion criteria: Individuals with malnutrition Individuals with alcohol consumption taking lipid-lowering drugs following special diets such as vegetarian or raw vegetarian diseases such as diabetes mellitus, cardiovascular disease, liver disease (cirrhosis, alcoholic liver disease, viral hepatitis, autoimmune hepatitis, primary biliary cirrhosis, biliary obstruction, hepatic injury induced by hereditary hemochromatosis drugs, sclerosis cholangitis, and a antisense deficiency), cancer, renal failure, celiac; being in pregnancy and lactation. taking Drugs that cause fatty liver (methotrexate, tamoxifen, valproate, etc.)

Design outcomes

Primary

Measure	Time frame
The degree of fatty liver. Timepoint: Before and after 8 weeks of intervention. Method of measurement: liver ultrasound.	—

Secondary

Measure	Time frame
Anthropometric indices. Timepoint: Before and after 8 weeks of intervention. Method of measurement: Digital scales and tape meters.;Lipid profile. Timepoint: Before and after 8 weeks of intervention. Method of measurement: Kit.;Systolic and diastolic blood pressure. Timepoint: Before and after 8 weeks of intervention. Method of measurement: Mercury barometer.;Blood sugar indices. Timepoint: Before and after 8 weeks of intervention. Method of measurement: Kit.;Inflammatory indices. Timepoint: Before and after 8 weeks of intervention. Method of measurement: enzyme-linked immunosorbent assay( ELISA)kit.;Liver enzymes. Timepoint: Before and after 8 weeks of intervention. Method of measurement: Kit.	—

Measure

Time frame

Anthropometric indices. Timepoint: Before and after 8 weeks of intervention. Method of measurement: Digital scales and tape meters.;Lipid profile. Timepoint: Before and after 8 weeks of intervention. Method of measurement: Kit.;Systolic and diastolic blood pressure. Timepoint: Before and after 8 weeks of intervention. Method of measurement: Mercury barometer.;Blood sugar indices. Timepoint: Before and after 8 weeks of intervention. Method of measurement: Kit.;Inflammatory indices. Timepoint: Before and after 8 weeks of intervention. Method of measurement: enzyme-linked immunosorbent assay( ELISA)kit.;Liver enzymes. Timepoint: Before and after 8 weeks of intervention. Method of measurement: Kit.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactReza Barati

Shiraz University of Medical Sciences

reza93barati@gmail.com+98 71 3612 2206

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026